

Annexure-A

Disclosure under Regulation 30 Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name of the target entity	Ajoooni Life Sciences Private Limited.																
Whether the acquisition would fall within related party transaction and whether the promoter/promoter group/group companies have any interest in the entity being acquired	Yes																
Industry to which the entity being acquired belongs	Marketing and selling of products through Television, Electronic Media, Print Media or any other mode.																
Object and effects of acquisition	This strategic acquisition will enable the company to gain control and align operations more closely with our company's long term vision. It will provide us with greater flexibility in decision making.																
Any governmental or regulatory approval required for the acquisition	No																
Indicative time period for completion of the acquisition	Expected to close by June 2025																
Nature of consideration	Cash																
Cost of acquisition or the price at which the shares are acquired	Rs. 5 lacs approx.																
Percentage of holding	100% of the equity share capital																
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Company incorporated in 26/06/2023. The main business of the company is Marketing and selling of products through Television, Electronic Media, Print Media or any other mode.</p> <p>Audited Financials in brief: (In hundreds)</p> <table border="1"> <thead> <tr> <th>Particulars</th> <th>2023-24</th> <th>2022-23</th> <th>2021-22</th> </tr> </thead> <tbody> <tr> <td>Turnover</td> <td>15038.95</td> <td>-</td> <td>-</td> </tr> <tr> <td>EBIDTA</td> <td>(1930.05)</td> <td>-</td> <td>-</td> </tr> <tr> <td>PAT</td> <td>(1930.05)</td> <td>-</td> <td>-</td> </tr> </tbody> </table>	Particulars	2023-24	2022-23	2021-22	Turnover	15038.95	-	-	EBIDTA	(1930.05)	-	-	PAT	(1930.05)	-	-
Particulars	2023-24	2022-23	2021-22														
Turnover	15038.95	-	-														
EBIDTA	(1930.05)	-	-														
PAT	(1930.05)	-	-														